MetLife Investment Management’s Castle Biosciences CSTL Stock Holding History

MetLife Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$406K	Buy	17,008 +286	+2%	+$6.37K	﹤0.01%	2041
2026 Q1	$411K	Buy	16,722 +841	+5%	+$27.5K	﹤0.01%	1842
2025 Q4	$618K	Hold	15,881	–	–	﹤0.01%	1691
2025 Q3	$362K	Hold	15,881	–	–	﹤0.01%	1971
2025 Q2	$324K	Buy	15,881 +152	+1%	+$2.81K	﹤0.01%	1909
2025 Q1	$315K	Sell	15,729 -288	-2%	-$7.13K	﹤0.01%	1946
2024 Q4	$427K	Buy	16,017 +1,645	+11%	+$50.1K	﹤0.01%	1887
2024 Q3	$410K	Hold	14,372	–	–	﹤0.01%	1887
2024 Q2	$313K	Buy	14,372 +2,003	+16%	+$44.6K	﹤0.01%	1982
2024 Q1	$274K	Hold	12,369	–	–	﹤0.01%	2009
2023 Q4	$267K	Hold	12,369	–	–	﹤0.01%	2070
2023 Q3	$209K	Hold	12,369	–	–	﹤0.01%	2181
2023 Q2	$170K	Hold	12,369	–	–	﹤0.01%	2379
2023 Q1	$281K	Hold	12,369	–	–	﹤0.01%	2008
2022 Q4	$291K	Hold	12,369	–	–	﹤0.01%	2010
2022 Q3	$323K	Hold	12,369	–	–	﹤0.01%	1955
2022 Q2	$272K	Hold	12,369	–	–	﹤0.01%	2093
2022 Q1	$555K	Buy	12,369 +4,565	+58%	+$189K	﹤0.01%	1708
2021 Q4	$335K	Hold	7,804	–	–	﹤0.01%	1737
2021 Q3	$519K	Hold	7,804	–	–	﹤0.01%	1499
2021 Q2	$572K	Buy	7,804 +2,020	+35%	+$133K	0.01%	1488
2021 Q1	$396K	Buy	5,784 +1,176	+26%	+$88.4K	﹤0.01%	1660
2020 Q4	$309K	Hold	4,608	–	–	﹤0.01%	1753
2020 Q3	$237K	Hold	4,608	–	–	﹤0.01%	1762
2020 Q2	$174K	Hold	4,608	–	–	﹤0.01%	1987
2020 Q1	$137K	Buy	+4,608	New	+$139K	﹤0.01%	1896

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's CSTL Position: Q2 2026 in Review

MetLife Investment Management increased its Castle Biosciences (CSTL) stake by 1.7% in Q2 2026, buying an estimated $6.37K and bringing the position to 17,008 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

MetLife Investment Management first reported a position in CSTL in Q1 2020 and has held it in 26 quarters since. The position peaked at $618K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

MetLife Investment Management held 17,008 shares of Castle Biosciences worth $406K as of Q2 2026.
MetLife Investment Management bought 286 Castle Biosciences shares in Q2 2026, an estimated $6.37K.
Castle Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2041 holding.
MetLife Investment Management first reported a position in Castle Biosciences in Q1 2020 and has held it in 26 quarters since.
MetLife Investment Management's Castle Biosciences position peaked at $618K in Q4 2025.
177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.